Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal.

Myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and related disorders are a heterogeneous class of blood cancers leading to ineffective hematopoiesis in the bone marrow (BM) [1, 2]. Approximately 30% of MDS patients progress to acute leukemia. Median survival ranges from 97 months for low risk categories, down to 11 months for high risk MDS [2]. The incidence of MDS in the general population is ∼4-5 per 100,000 people, but this increases with age [1]. Population based studies in both Australia and the USA indicate a significant underestimation of the true burden of MDS, with frequencies estimated at 103 per 100,000 and between 75-162 per 100,000 respectively over age 65 [3-5].

Source: Experimental Hematology - November 6, 2018 Category: Hematology Authors: Jane Jialu Xu, Monique F Smeets, Shuh Ying Tan, Meaghan Wall, Louise E. Purton, Carl R Walkley Tags: Review Source Type: research